Core Telehealth Revenue Growth
Core Telehealth business experienced a 70% year-over-year revenue growth, driven by the weight management program, with adjusted EBITDA reaching $5.3 million, a significant improvement from a loss of $1.3 million in the previous year.
Strategic Expansion and Collaborations
LifeMD has established strategic collaborations with LillyDirect and NovoCare to improve access to GLP-1 medications for weight management patients, enhancing its competitive position in virtual obesity care.
Positive GAAP Net Income
LifeMD reported a GAAP net income of $608,000 for the first quarter, marking the first quarter with positive GAAP net income, compared to a loss of $7.5 million in the previous year.
Growth in Subscriber Base
Telehealth subscriber base increased by 22% year-over-year to over 290,000, indicating strong customer retention and acquisition.
RexMD Brand Performance
The RexMD brand continues to perform well with growth in revenue and active patient count, especially in new verticals like hormone replacement therapy.
Expansion into New Verticals
LifeMD is entering high-growth verticals such as women’s health and behavioral health, which are expected to contribute to revenue diversification and long-term profitability.
Increased Financial Guidance
Due to the strong performance of the Telehealth business, LifeMD raised its financial guidance for 2025 with expected total revenues between $268 million to $275 million.